Surekha Surendranathan
Overview
Explore the profile of Surekha Surendranathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanders B, Pokhrel S, Labbe A, Mathews I, Cooper C, Davidson R, et al.
Nat Commun
. 2023 Mar;
14(1):1733.
PMID: 36977673
Direct-acting antivirals are needed to combat coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The papain-like protease (PLpro) domain of Nsp3 from SARS-CoV-2 is essential...
2.
Joshi R, Schultz K, Wilson J, Kruel A, Varikoti R, Kombala C, et al.
J Chem Inf Model
. 2023 Feb;
63(5):1438-1453.
PMID: 36808989
Direct-acting antivirals for the treatment of the COVID-19 pandemic caused by the SARS-CoV-2 virus are needed to complement vaccination efforts. Given the ongoing emergence of new variants, automated experimentation, and...
3.
Sanders B, Pokhrel S, Labbe A, Mathews I, Cooper C, Davidson R, et al.
Res Sq
. 2022 Jul;
PMID: 35898342
Direct-acting antivirals are needed to combat coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The papain-like protease (PLpro) domain of Nsp3 from SARS-CoV-2 is essential...
4.
Kneller D, Li H, Phillips G, Weiss K, Zhang Q, Arnould M, et al.
Nat Commun
. 2022 Apr;
13(1):2268.
PMID: 35477935
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19 vaccines, and small-molecule antivirals can provide an important therapeutic treatment option. The viral main protease (M) is critical for virus...
5.
Kneller D, Li H, Phillips G, Weiss K, Zhang Q, Arnould M, et al.
Res Sq
. 2022 Feb;
PMID: 35169792
The COVID-19 pandemic continues to disrupt everyday life, with constantly emerging SARS-CoV-2 variants threatening to render current vaccines ineffective. Small-molecule antivirals can provide an important therapeutic treatment option that is...
6.
Banerjee S, Yadav S, Banerjee S, O Fakayode S, Parvathareddy J, Reichard W, et al.
J Chem Inf Model
. 2021 Oct;
61(11):5469-5483.
PMID: 34666487
COVID-19, an acute viral pneumonia, has emerged as a devastating pandemic. Drug repurposing allows researchers to find different indications of FDA-approved or investigational drugs. In this current study, a sequence...
7.
Sanders B, Pokhrel S, Labbe A, Mathews I, Cooper C, Davidson R, et al.
Res Sq
. 2021 Oct;
PMID: 34642689
Direct-acting antivirals are needed to combat coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The papain-like protease (PLpro) domain of Nsp3 from SARS-CoV-2 is essential...
8.
Bocci G, Bradfute S, Ye C, Garcia M, Parvathareddy J, Reichard W, et al.
ACS Pharmacol Transl Sci
. 2020 Dec;
3(6):1278-1292.
PMID: 33330842
The urgent need for a cure for early phase COVID-19 infected patients critically underlines drug repositioning strategies able to efficiently identify new and reliable treatments by merging computational, experimental, and...